What’s Up With Diagnostics and Tools Stocks? Big Winners Are In Personalized Medicine- FMI, ILMN

Clinical Diagnostics and Tools: Big Winners Are In Genomics and Personalized Medicine Slower growth in routine clinical diagnostics, tools are favored. Hologic has a unique business model for women’s health and diagnostics. Gene sequencing is important for future clinical applications and biopharma R&D. We haven’t updated our Clinical Diagnostics and Tools Portfolio since the severe […]

Continue Reading 0

Macro Headwinds Stall Biotech Stocks and ASH Momentum Fades…Update-1

Update 12/18 Market Rockets to Records But Biotechs Left Behind Ebullience reigned today stoked by tax cuts around the corner. Although many talking heads have said that the tax cuts are “baked in” it seems that a new view has emerged that equities still have room to run because of stock buybacks, capital investment, dividend […]

Continue Reading 0

Rayno BioBeat #7: Biotech Green Screen Day Off Recent Bottom…Update-2

Update 12/12/17 Biotech Rally Stalls at Resistance Celgene (CELG) holds $109. Mid-caps red especially INCY PTLA RDUS. Mixed market on low volume. Alexion (ALXN) trying to bounce. =============== Update 12/10/17 Can the biotech rally continue this week with ASH news? XBI hits $84 the one month peak IBB at $106 the one month peak Celgene […]

Continue Reading 0

West Coast Weather Update: LaNina Dry Pattern for Week Ahead-Weather Update…12/29/17

Upate 12/29/17 High Pressure in Control Until Late Next week Looks like finally we may get a breakthrough with storms making it into California. We we will provide a detailed update by Monday. Above normal Ppt for SoCal 8-10 day model Outlook through Jan 3 ========= Update 12/12/17 Dry Pattern Will Continue in California Jet […]

Continue Reading 0

Sluggish Biotech Stocks: Five Underlying Factors Plus A Sector Shift?

MegaCap Tech Stocks Take a Big Hit-Volatility Rising in a Sector Shift Market Rotation Supports Overall Market-S&P 500 Stable today up 17% YTD Sluggish Biotech Now Just a Market Performer With IBB up 17% YTD The booming tech sector sold off today with the XLK down over 2%. Harder hit were the 2017 high fliers […]

Continue Reading 0

Rayno Biopharmaceutical Portfolio Update with Biotech Holding: CELG,RHHBY,XBI…Update 11/29 Rotation Day

11/29/17 Market Reversal in Early Trading 11:35a -FAANG sell-off Stocks show a rotation out of technology and into financials and cyclical consumer goods. XLK is down 2.2%, XLV up 0.66%, IBB up 0.42% with large caps holding. 11/28/17 Biotechs Treading Water But Many Good Opportunities Exist Biotechs show a lack of momentum but are holding […]

Continue Reading 0

Biotech Correction: Just a market rotation or slower growth ahead?

Biotech Correction: Sell-Off Has Reached 10% over Three Months Biotechs under pressure-has revenue growth slowed? Technicals-a break through bottom channel. Need a bounce today. Celgene is a bellwether. A buy in the $102 range. Biotech stocks have been weak since Q4 earnings were reported and despite gains of about 15% or more year-to-date (IBB), warning […]

Continue Reading 0

LaNina is Here with First Major West Coast Storm of Season in Coming Days

A LaNina Advisory was Issued on November 9 This weak LaNina generally affects climate as follows: “The outlooks generally favor above-average temperatures and below-median precipitation across the southern tier of the United States, and below-average temperatures and above- median precipitation across the northern tier of the United States.” In previous years LaNina has delivered great […]

Continue Reading 0

Biotech Hangover: Recent Earnings Feed Caution with No Near Term Catalysts

Biotech Hangover from Earnings Clouds Outlook Healthcare sector (XLV) lagging technology (QQQ) and FAANG stocks. No earnings catalysts until Jan 2018 but Q4 has seen strong seasonality. Technicals rule as sellers predominate. Bull market is intact. On October 16 we posted that Risks were Rising for the 2017 biotech rally primarily because technicals were weakening […]

Continue Reading 0

Rayno Biopharmaceutical Portfolio Update: Buy and Hold is the Key…Update-2

Update 11/8/17 …Per comments on Monday. Celgene (CELG) technicals are holding at $102-103 so we will add CELG to the Rayno Portfolio at a price of ~$102.5. The stock was battered on earnings news so we see good value and potential for long term growth. Forward PE is 11.74, Price/Sales is 6.33. Risk is balance […]

Continue Reading 0